These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 31350632)

  • 1. Intravenous gadolinium-based hepatocyte-specific contrast agents (HSCAs) for contrast-enhanced liver magnetic resonance imaging in pediatric patients: what the radiologist should know.
    Ayyala RS; Anupindi SA; Gee MS; Trout AT; Callahan MJ
    Pediatr Radiol; 2019 Sep; 49(10):1256-1268. PubMed ID: 31350632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical use and pitfalls of hepatocyte-specific contrast agents (HSCAs) for pediatric hepatic and biliary magnetic resonance imaging.
    Ayyala RS; Anupindi SA; Callahan MJ
    Abdom Radiol (NY); 2017 Feb; 42(2):502-520. PubMed ID: 27680015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Pictorial Review of Hepatobiliary Magnetic Resonance Imaging With Hepatocyte-Specific Contrast Agents: Uses, Findings, and Pitfalls of Gadoxetate Disodium and Gadobenate Dimeglumine.
    Scali EP; Walshe T; Tiwari HA; Harris AC; Chang SD
    Can Assoc Radiol J; 2017 Aug; 68(3):293-307. PubMed ID: 28583364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocyte-specific contrast agent-enhanced magnetic resonance cholangiography: perioperative evaluation of the biliary tree.
    Zattar-Ramos LC; Bezerra ROF; Siqueira LTB; Menezes MR; Leite CDC; Cerri GG
    Radiol Bras; 2017; 50(6):389-394. PubMed ID: 29307930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadolinium-based contrast agents in pediatric magnetic resonance imaging.
    Gale EM; Caravan P; Rao AG; McDonald RJ; Winfeld M; Fleck RJ; Gee MS
    Pediatr Radiol; 2017 May; 47(5):507-521. PubMed ID: 28409250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging of primary pediatric liver tumors.
    Pugmire BS; Towbin AJ
    Pediatr Radiol; 2016 May; 46(6):764-77. PubMed ID: 27229495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents.
    Goodwin MD; Dobson JE; Sirlin CB; Lim BG; Stella DL
    Radiographics; 2011 Oct; 31(6):1547-68. PubMed ID: 21997981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imaging.
    Burke C; Alexander Grant L; Goh V; Griffin N
    Semin Ultrasound CT MR; 2013 Feb; 34(1):44-53. PubMed ID: 23395317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrast enhanced liver MRI in patients with primary sclerosing cholangitis: inverse appearance of focal confluent fibrosis on delayed phase MR images with hepatocyte specific versus extracellular gadolinium based contrast agents.
    Husarik DB; Gupta RT; Ringe KI; Boll DT; Merkle EM
    Acad Radiol; 2011 Dec; 18(12):1549-54. PubMed ID: 21958599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gaucher disease in the liver on hepatocyte specific contrast agent enhanced MR imaging.
    Ayyala RS; Teot LA; Perez Rossello JM
    Pediatr Radiol; 2017 Apr; 47(4):484-487. PubMed ID: 28144704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gadolinium contrast agent selection and optimal use for body MR imaging.
    Guglielmo FF; Mitchell DG; Gupta S
    Radiol Clin North Am; 2014 Jul; 52(4):637-56. PubMed ID: 24889165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocyte-specific contrast media: not so simple.
    Trout AT; Towbin AJ; Smith EA; Gupta A; Dillman JR
    Pediatr Radiol; 2018 Aug; 48(9):1245-1255. PubMed ID: 30078050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic MR imaging of the biliary system using hepatocyte-specific contrast agents.
    Gupta RT; Brady CM; Lotz J; Boll DT; Merkle EM
    AJR Am J Roentgenol; 2010 Aug; 195(2):405-13. PubMed ID: 20651197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of gadolinium-based magnetic resonance imaging contrast agents and awareness of brain gadolinium deposition among pediatric providers in North America.
    Mithal LB; Patel PS; Mithal D; Palac HL; Rozenfeld MN
    Pediatr Radiol; 2017 May; 47(6):657-664. PubMed ID: 28283727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
    Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
    Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of magnetic resonance imaging contrast agents in the liver and biliary tract.
    Lebedis C; Luna A; Soto JA
    Magn Reson Imaging Clin N Am; 2012 Nov; 20(4):715-37. PubMed ID: 23088947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadolinium based contrast agents (GBCA): Safety overview after 3 decades of clinical experience.
    Kanal E
    Magn Reson Imaging; 2016 Dec; 34(10):1341-1345. PubMed ID: 27608608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance contrast agents for liver imaging.
    Bashir MR
    Magn Reson Imaging Clin N Am; 2014 Aug; 22(3):283-93. PubMed ID: 25086930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Part 2: MRI of hypervascular focal liver lesions using liver specific contrast agents.
    Sutherland T; Seale M; Yap K
    J Med Imaging Radiat Oncol; 2014 Feb; 58(1):56-63. PubMed ID: 24529056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadolinium Presence in the Brain After Administration of the Liver-Specific Gadolinium-Based Contrast Agent Gadoxetate: A Systematic Comparison to Multipurpose Agents in Rats.
    Jost G; Frenzel T; Boyken J; Schoeckel L; Pietsch H
    Invest Radiol; 2019 Aug; 54(8):468-474. PubMed ID: 30932931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.